Horizant gabapentin enacarbil: Phase II started

XenoPort said NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the double-blind, placebo-controlled, U.S. Phase II NCIG-006 trial to evaluate 600 mg oral Horizant twice daily for...